Insulin, insulin receptors, and cancer

Journal of Endocrinological Investigation

Volumn 39, Issue 12, 2016, Pages 1365-1376

  Vigneri, R ^a,b,c,d   Goldfine, I D ^e   Frittitta, L ^a,b  

^a Garibaldi Nesima Medical Center   (Italy)

^b UNIVERSITY OF CATANIA   (Italy)

^c Catania Cancer Center   (Italy)

^d CNR   (Italy)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Diabetes and cancer; Hybrid receptors; Insulin; Insulin receptor; IR isoforms

Indexed keywords

INSULIN; INSULIN RECEPTOR; MEMBRANE RECEPTOR; PROTEIN TYROSINE KINASE; SOMATOMEDIN C RECEPTOR;

BINDING AFFINITY; CANCER CELL; CANCER GROWTH; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; GENE OVEREXPRESSION; HORMONE RECEPTOR INTERACTION; HUMAN; HYPERINSULINEMIA; IMPAIRED GLUCOSE TOLERANCE; IN VITRO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; METABOLIC SYNDROME X; MITOGENESIS; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OVARY POLYCYSTIC DISEASE; PROTEIN FAMILY; REVIEW; SIGNAL TRANSDUCTION; TARGET CELL; METABOLISM; PATHOPHYSIOLOGY;

HUMANS; INSULIN; NEOPLASMS; RECEPTOR, INSULIN;

EID: 84994872058     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.1007/s40618-016-0508-7     Document Type: Review

References (99)

1. Taniguchi CM, Emanuelli B, Kahn CR (2006) Critical nodes in signalling pathways: insights into insulin action. Nat Rev Mol Cell Biol 7(2):85–96
2. Ebina Y et al (1985) The human insulin receptor cDNA: the structural basis for hormone-activated transmembrane signalling. Cell 40(4):747–758
3. Ward CW, Lawrence MC (2009) Ligand-induced activation of the insulin receptor: a multi-step process involving structural changes in both the ligand and the receptor. BioEssays 31(4):422–434
4. Brogiolo W et al (2001) An evolutionarily conserved function of the Drosophila insulin receptor and insulin-like peptides in growth control. Curr Biol 11(4):213–221
5. Frasca F et al (1999) Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells. Mol Cell Biol 19(5):3278–3288
6. Giddings SJ, Carnaghi LR (1992) Insulin receptor gene expression during development: developmental regulation of insulin receptor mRNA abundance in embryonic rat liver and yolk sac, developmental regulation of insulin receptor gene splicing, and comparison to abundance of insulin-like growth factor 1 receptor mRNA. Mol Endocrinol 6(10):1665–1672
7. Belfiore A (2007) The role of insulin receptor isoforms and hybrid insulin/IGF-I receptors in human cancer. Curr Pharm Des 13(7):671–686
8. Kasuya J et al (1993) Characterization of human placental insulin-like growth factor-I/insulin hybrid receptors by protein microsequencing and purification. Biochemistry 32(49):13531–13536
9. Benyoucef S et al (2007) Characterization of insulin/IGF hybrid receptors: contributions of the insulin receptor L2 and Fn1 domains and the alternatively spliced exon 11 sequence to ligand binding and receptor activation. Biochem J 403(3):603–613
10. Siddle K et al (2001) Specificity in ligand binding and intracellular signalling by insulin and insulin-like growth factor receptors. Biochem Soc Trans 29(Pt 4):513–525
11. Lammers R et al (1989) Differential signalling potential of insulin- and IGF-1-receptor cytoplasmic domains. EMBO J 8(5):1369–1375
12. Denley A et al (2004) Structural determinants for high-affinity binding of insulin-like growth factor II to insulin receptor (IR)-A, the exon 11 minus isoform of the IR. Mol Endocrinol 18(10):2502–2512
13. Belfiore A, Malaguarnera R (2011) Insulin receptor and cancer. Endocr Relat Cancer 18(4):R125–R147
14. Malaguarnera R et al (2012) Proinsulin binds with high affinity the insulin receptor isoform A and predominantly activates the mitogenic pathway. Endocrinology 153(5):2152–2163
15. Frasca F et al (2003) Insulin and hybrid insulin/IGF receptors are major regulators of breast cancer cells. Breast Dis 17:73–89
16. Kurtzhals P et al (2000) Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 49(6):999–1005
17. Sciacca L, Le Moli R, Vigneri R (2012) Insulin analogs and cancer. Front Endocrinol 3:21
18. Vigneri P et al (2009) Diabetes and cancer. Endocr Relat Cancer 16(4):1103–1123
19. Rose DP, Vona-Davis L (2012) The cellular and molecular mechanisms by which insulin influences breast cancer risk and progression. Endocr Relat Cancer 19(6):R225–R241
20. Giovannucci E et al (2010) Diabetes and cancer: a consensus report. Diabetes Care 33(7):1674–1685
21. Bailyes EM et al (1997) Insulin receptor/IGF-I receptor hybrids are widely distributed in mammalian tissues: quantification of individual receptor species by selective immunoprecipitation and immunoblotting. Biochem J 327(Pt 1):209–215
22. White MF (1998) The IRS-signalling system: a network of docking proteins that mediate insulin action. Mol Cell Biochem 182(1–2):3–11
23. Belfiore A et al (2009) Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocr Rev 30(6):586–623
24. Milazzo G et al (1992) Insulin receptor expression and function in human breast cancer cell lines. Cancer Res 52(14):3924–3930
25. Frittitta L et al (1997) The insulin receptor content is increased in breast cancers initiated by three different oncogenes in transgenic mice. Breast Cancer Res Treat 45(2):141–147
26. Osborne CK et al (1978) Correlation among insulin binding, degradation, and biological activity in human breast cancer cells in long-term tissue culture. Cancer Res 38(1):94–102
27. Frittitta L et al (1993) Structural and functional studies of insulin receptors in human breast cancer. Breast Cancer Res Treat 25(1):73–82
28. Papa V et al (1990) Elevated insulin receptor content in human breast cancer. J Clin Invest 86(5):1503–1510
29. Vella V et al (2001) The IGF system in thyroid cancer: new concepts. Mol Pathol 54(3):121–124
30. Aiello A et al (2010) HMGA1 protein is a positive regulator of the insulin-like growth factor-I receptor gene. Eur J Cancer 46(10):1919–1926
31. Chiefari E et al (2013) A polymorphism of HMGA1 is associated with increased risk of metabolic syndrome and related components. Sci Rep 3:1491
32. Fusco A, Fedele M (2007) Roles of HMGA proteins in cancer. Nat Rev Cancer 7(12):899–910
33. Sciacca L et al (2002) In IGF-I receptor-deficient leiomyosarcoma cells autocrine IGF-II induces cell invasion and protection from apoptosis via the insulin receptor isoform A. Oncogene 21(54):8240–8250
34. Vella V et al (2002) A novel autocrine loop involving IGF-II and the insulin receptor isoform-A stimulates growth of thyroid cancer. J Clin Endocrinol Metab 87(1):245–254
35. Kalli KR et al (2002) Functional insulin receptors on human epithelial ovarian carcinoma cells: implications for IGF-II mitogenic signaling. Endocrinology 143(9):3259–3267
36. Soos MA et al (1990) Receptors for insulin and insulin-like growth factor-I can form hybrid dimers. Characterisation of hybrid receptors in transfected cells. Biochem J 270(2):383–390
37. Spampinato D et al (2000) Insulin/insulin-like growth factor I hybrid receptors overexpression is not an early defect in insulin-resistant subjects. J Clin Endocrinol Metab 85(11):4219–4223
38. Pandini G et al (1999) Insulin and insulin-like growth factor-I (IGF-I) receptor overexpression in breast cancers leads to insulin/IGF-I hybrid receptor overexpression: evidence for a second mechanism of IGF-I signaling. Clin Cancer Res 5(7):1935–1944
39. Pandini G et al (2007) Functional responses and in vivo anti-tumour activity of h7C10: a humanised monoclonal antibody with neutralising activity against the insulin-like growth factor-1 (IGF-1) receptor and insulin/IGF-1 hybrid receptors. Eur J Cancer 43(8):1318–1327
40. Pandini G et al (2002) Insulin/insulin-like growth factor I hybrid receptors have different biological characteristics depending on the insulin receptor isoform involved. J Biol Chem 277(42):39684–39695
41. Lukanova A et al (2004) Body mass index, circulating levels of sex-steroid hormones, IGF-I and IGF-binding protein-3: a cross-sectional study in healthy women. Eur J Endocrinol 150(2):161–171
42. Jenab M et al (2007) Serum C-peptide, IGFBP-1 and IGFBP-2 and risk of colon and rectal cancers in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer 121(2):368–376
43. Inzucchi SE (2002) Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA 287(3):360–372
44. Bo S et al (2012) Does use of metformin protect against cancer in Type 2 diabetes mellitus? J Endocrinol Invest 35(2):231–235
45. Coperchini F et al (2015) Expanding the therapeutic spectrum of metformin: from diabetes to cancer. J Endocrinol Invest 38(10):1047–1055
46. Giorgino F et al (1991) Overexpression of insulin receptors in fibroblast and ovary cells induces a ligand-mediated transformed phenotype. Mol Endocrinol 5(3):452–459
47. Sciacca L et al (2013) Clinical and molecular mechanisms favoring cancer initiation and progression in diabetic patients. Nutr Metab Cardiovasc Dis 23(9):808–815
48. Frittitta L et al (1995) Insulin receptor overexpression in 184B5 human mammary epithelial cells induces a ligand-dependent transformed phenotype. J Cell Biochem 57(4):666–669
49. Shafie SM, Grantham FH (1981) Role of hormones in the growth and regression of human breast cancer cells (MCF-7) transplanted into athymic nude mice. J Natl Cancer Inst 67(1):51–56
50. Wang YH, Scadden DT (2015) Targeting the Warburg effect for leukemia therapy: magnitude matters. Mol Cell Oncol 2(3):e981988
51. Srinivasan S, Guha M, Avadhani NG (2016) Mitochondrial respiratory defects promote the Warburg effect and cancer progression. Mol Cell Oncol 3(2):e1085120
52. Muti P et al (2002) Fasting glucose is a risk factor for breast cancer: a prospective study. Cancer Epidemiol Biomark Prev 11(11):1361–1368
53. Krone CA, Ely JT (2005) Controlling hyperglycemia as an adjunct to cancer therapy. Integr Cancer Ther 4(1):25–31
54. Boyle P et al (2013) Blood glucose concentrations and breast cancer risk in women without diabetes: a meta-analysis. Eur J Nutr 52(5):1533–1540
55. Carstensen B et al (2016) Cancer incidence in persons with type 1 diabetes: a five-country study of 9,000 cancers in type 1 diabetic individuals. Diabetologia 59(5):980–988
56. Huang Y et al (2014) Prediabetes and the risk of cancer: a meta-analysis. Diabetologia 57(11):2261–2269
57. Shin HY et al (2014) Association between fasting serum glucose levels and incidence of colorectal cancer in Korean men: the Korean Cancer Prevention Study-II. Metabolism 63(10):1250–1256
58. Parekh N et al (2013) Metabolic dysregulation of the insulin-glucose axis and risk of obesity-related cancers in the Framingham heart study-offspring cohort (1971-2008). Cancer Epidemiol Biomark Prev 22(10):1825–1836
59. Buysschaert M et al (2015) Prediabetes and associated disorders. Endocrine 48(2):371–393
60. Ahn HK et al (2015) Metabolic components and recurrence in early-stage cervical cancer. Tumour Biol 36(3):2201–2207
61. Cowey S, Hardy RW (2006) The metabolic syndrome: a high-risk state for cancer? Am J Pathol 169(5):1505–1522
62. Trabert B et al (2015) Metabolic syndrome and risk of endometrial cancer in the united states: a study in the SEER-medicare linked database. Cancer Epidemiol Biomark Prev 24(1):261–267
63. Bhindi B et al (2015) Dissecting the association between metabolic syndrome and prostate cancer risk: analysis of a large clinical cohort. Eur Urol 67(1):64–70
64. Vigneri P et al (2006) Obesity and cancer. Nutr Metab Cardiovasc Dis 16(1):1–7
65. von Hafe P et al (2004) Visceral fat accumulation as a risk factor for prostate cancer. Obes Res 12(12):1930–1935
66. Stoll BA (2002) Upper abdominal obesity, insulin resistance and breast cancer risk. Int J Obes Relat Metab Disord 26(6):747–753
67. Weichhaus M et al (2012) A novel role for insulin resistance in the connection between obesity and postmenopausal breast cancer. Int J Oncol 41(2):745–752
68. Calle EE et al (2003) Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348(17):1625–1638
69. Parekh N et al (2015) Insulin receptor variants and obesity-related cancers in the Framingham Heart Study. Cancer Causes Control 26(8):1189–1195
70. Emerging Risk Factors Collaboration et al (2011) Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 364(9):829–841
71. Mayer SB, Evans WS, Nestler JE (2015) Polycystic ovary syndrome and insulin: our understanding in the past, present and future. Womens Health 11(2):137–149
72. Mortada R, Williams T (2015) Metabolic syndrome: polycystic ovary syndrome. FP Essent 435:30–42
73. Tokmak A et al (2014) Polycystic ovary syndrome and risk of endometrial cancer: a mini-review. Asian Pac J Cancer Prev 15(17):7011–7014
74. Palomba S et al (2015) Complications and challenges associated with polycystic ovary syndrome: current perspectives. Int J Womens Health 7:745–763
75. Barry JA, Azizia MM, Hardiman PJ (2014) Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update 20(5):748–758
76. Zendehdel K et al (2003) Cancer incidence in patients with type 1 diabetes mellitus: a population-based cohort study in Sweden. J Natl Cancer Inst 95(23):1797–1800
77. Ebeling P, Tuominen JA, Koivisto VA (1996) Insulin analogues and carcinoma of the breast. Diabetologia 39(1):124–125
78. ter Braak B et al (2015) Mammary gland tumor promotion by chronic administration of IGF1 and the insulin analogue AspB10 in the p53R270H/(+)WAPCre mouse model. Breast Cancer Res 17:14
79. Milazzo G et al (1997) ASPB10 insulin induction of increased mitogenic responses and phenotypic changes in human breast epithelial cells: evidence for enhanced interactions with the insulin-like growth factor-I receptor. Mol Carcinog 18(1):19–25
80. Sciacca L et al (2010) Insulin analogues differently activate insulin receptor isoforms and post-receptor signalling. Diabetologia 53(8):1743–1753
81. Hemkens LG et al (2009) Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 52(9):1732–1744
82. Colhoun, H.M. and S.E. Group (2009) Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia 52(9):1755–1765
83. Currie CJ, Poole CD, Gale EA (2009) The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 52(9):1766–1777
84. Jonasson JM et al (2009) Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden. Diabetologia 52(9):1745–1754
85. Mannucci E et al (2010) Doses of insulin and its analogues and cancer occurrence in insulin-treated type 2 diabetic patients. Diabetes Care 33(9):1997–2003
86. Pocock SJ, Smeeth L (2009) Insulin glargine and malignancy: an unwarranted alarm. Lancet 374(9689):511–513
87. Garg SK, Hirsch IB, Skyler JS (2009) Insulin glargine and cancer—an unsubstantiated allegation. Diabetes Technol Ther 11(8):473–476
88. Suissa S et al (2011) Long-term effects of insulin glargine on the risk of breast cancer. Diabetologia 54(9):2254–2262
89. Ruiter R et al (2012) Risk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin: results from a large population-based follow-up study. Diabetologia 55(1):51–62
90. Investigators OT et al (2012) Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 367(4):319–328
91. Vigneri R, Vigneri P, Frittitta L (2012) Basal insulin and cardiovascular and other outcomes. N Engl J Med 367(18):1761–1762 (author reply 1763-4)
92. Mathieu MC et al (1997) Insulin receptor expression and clinical outcome in node-negative breast cancer. Proc Assoc Am Physicians 109(6):565–571
93. Law JH et al (2008) Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res 68(24):10238–10246
94. Kim JS et al (2012) Prognostic impact of insulin receptor expression on survival of patients with nonsmall cell lung cancer. Cancer 118(9):2454–2465
95. Helle SI (2004) The insulin-like growth factor system in advanced breast cancer. Best Pract Res Clin Endocrinol Metab 18(1):67–79
96. Janssen JA, Varewijck AJ (2014) IGF-IR Targeted Therapy: past, present and future. Front Endocrinol 5:224
97. Rostoker R et al (2015) Highly specific role of the insulin receptor in breast cancer progression. Endocr Relat Cancer 22(2):145–157
98. Sciacca L et al (2014) Biological effects of insulin and its analogs on cancer cells with different insulin family receptor expression. J Cell Physiol 229(11):1817–1821
99. Parekh N et al (2010) Longitudinal associations of blood markers of insulin and glucose metabolism and cancer mortality in the third National Health and Nutrition Examination Survey. Cancer Causes Control 21(4):631–642